XNAS
MASS
Market cap472mUSD
Oct 19, Last price
11.43USD
1D
1.51%
1Q
55.51%
IPO
-77.37%
Name
908 Devices Inc.
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
908 Devices Inc. provides purpose-built handheld mass spectrometry and fourier transform infrared (FTIR) devices for use in vital health and safety applications. The company’s products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; XplorIR, a handheld device that uses FTIR spectroscopy to identify, quantify, and track gases and vapors; ThreatID, a portable FTIR device that rapidly detects and identifies approximately 28,000 unknown gas, vapor, powder, and liquid chemical hazards; ProtectIR, a handheld FTIR device that can identify approximately 23,000 solid and liquid chemical hazards; and VipIR, a handheld 3-in-1 analyzer that integrates FTIR, Raman spectroscopy, and smart spectral processing (SSP), a proprietary algorithm, to provide a single result from just one sample. It operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of Americas. The company was incorporated in 2012 and is headquartered in Burlington, Massachusetts.
Key people
E. Kevin Hrusovsky
Independent Chairman of the Board · since 2020
Kevin Knopp
President, Chief Executive Officer, Co-Founder, Director · since 2012
Chief Legal and Administrative Officer, Company Secretary · since 2023
Jon Frattaroli
Vice President - Strategy · since 2024
John Kenneweg
Vice President - Government · since 2019
Kevin Mccallion
Vice President - Production and New Product Introduction · since 2020
Don Osmer
Vice President - Human Resources · since 2023
Joseph Griffith
Chief Financial Officer, Treasurer · since 2014
Steve Davenport
Vice President - Commercial Sales · since 2021
Barbara Russo
Vice President of Marketing and Corporate Communications · since 2024
Christopher Brown
Co-Founder, Director · since 2025
Michele Leonhart
Director · since 2024
Independent Director · since 2012
Marcia Eisenberg
Independent Director · since 2021
Fenel Eloi
Independent Director · since 2021
Independent Director · since 2022
Mark Spoto
Independent Director · since 2012
Brandi Vann
Independent Director · since 2025
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||